Coverage
Filings
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.
| Zealand Pharma issues new shares in connection with the exercise of warrants |
| 9 Dec 2010 |
| Zealand Pharma Receives Milestone Payment from Helsinn Healthcare | 9 Dec 2010 |
| Reporting of transactions in shares by executive employees in Zealand Pharma A/S | 9 Dec 2010 |
| Registration of capital increase completed | 9 Dec 2010 |
| Reporting of transactions in shares by executive employees in Zealand Pharma A/S | 29 Nov 2010 |